Jingxian G, et al. - Through an external cohort study carried out on 116 patients with hepatocellular carcinoma in postoperative adjuvant transcatheter arterial chemoembolization (PA-TACE) group to 232 in the control group, the researchers intended to approve the clinical effectiveness of PA-TACE after liver resection and recognize the patients who could benefit most from PA-TACE. TNM stage, tumor size, and number, hepatitis B infection, spleen diameter, preoperative serum α-fetoprotein, alkaline phosphatase, γ-glutamyl transpeptidase and monocyte, and three risk signatures were identified as the prognostic predictors for PA-TACE. The treatment effectiveness was validated with the identification of late-stage tumors, portal hypertension, and high preoperative serum levels of α-fetoprotein, alkaline phosphatase, γ-glutamyl transpeptidase, and monocytes as the best candidates for PA-TACE.